Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m)

Paul Rock, T. S. Johnson, A. Cymerman, R. L. Burse, L. J. Falk, C. S. Fulco

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

In a previous controlled study, dexamethasone (DEX) was shown to prevent acute mountain sickness (AMS) during exposure to simulated high altitude. To determine the effect of DEX during actual altitude exposure, 16 young men were treated with either DEX (4 mg every 6 h) or placebo for 48 h prior to and 48 h after being repidly transported from sea level to the summit of Pokes Peak, CO (4,300 m). Symptoms of AMS were evaluated twice daily at Pikes Peak using the Environmental Symptoms Questionnaire and a clinical assessment. During treatment the mean symptom scores were higher for subjects taking placebo in 18 out of 20 comparisons. On an individual basis, 60% of the subjects receiving placebo met the criteria for being 'sick' compared to 31% of subjects receiving DEX. Beginning 24 h after cessation of treatment, DEX subjects experienced a progressive increase in symptom scores which lasted through the end of the altitude sojourn (day 6). The results indicate that DEX is an effective prophylactic treatment for AMS in an actual mountain environment, but that AMS symptoms can occur if the drug is stopped abruptly.

Original languageEnglish
Pages (from-to)668-672
Number of pages5
JournalAviation Space and Environmental Medicine
Volume58
Issue number7
StatePublished - 1 Dec 1987

Fingerprint

Esocidae
Altitude Sickness
Dexamethasone
Placebos
Withholding Treatment
Carbon Monoxide
Oceans and Seas
Therapeutics
Pharmaceutical Preparations

Cite this

Rock, P., Johnson, T. S., Cymerman, A., Burse, R. L., Falk, L. J., & Fulco, C. S. (1987). Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviation Space and Environmental Medicine, 58(7), 668-672.
Rock, Paul ; Johnson, T. S. ; Cymerman, A. ; Burse, R. L. ; Falk, L. J. ; Fulco, C. S. / Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). In: Aviation Space and Environmental Medicine. 1987 ; Vol. 58, No. 7. pp. 668-672.
@article{fa1eb61e90a9466fb475fc46730d2437,
title = "Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m)",
abstract = "In a previous controlled study, dexamethasone (DEX) was shown to prevent acute mountain sickness (AMS) during exposure to simulated high altitude. To determine the effect of DEX during actual altitude exposure, 16 young men were treated with either DEX (4 mg every 6 h) or placebo for 48 h prior to and 48 h after being repidly transported from sea level to the summit of Pokes Peak, CO (4,300 m). Symptoms of AMS were evaluated twice daily at Pikes Peak using the Environmental Symptoms Questionnaire and a clinical assessment. During treatment the mean symptom scores were higher for subjects taking placebo in 18 out of 20 comparisons. On an individual basis, 60{\%} of the subjects receiving placebo met the criteria for being 'sick' compared to 31{\%} of subjects receiving DEX. Beginning 24 h after cessation of treatment, DEX subjects experienced a progressive increase in symptom scores which lasted through the end of the altitude sojourn (day 6). The results indicate that DEX is an effective prophylactic treatment for AMS in an actual mountain environment, but that AMS symptoms can occur if the drug is stopped abruptly.",
author = "Paul Rock and Johnson, {T. S.} and A. Cymerman and Burse, {R. L.} and Falk, {L. J.} and Fulco, {C. S.}",
year = "1987",
month = "12",
day = "1",
language = "English",
volume = "58",
pages = "668--672",
journal = "Aviation Space and Environmental Medicine",
issn = "0095-6562",
publisher = "Aerospace Medical Association",
number = "7",

}

Rock, P, Johnson, TS, Cymerman, A, Burse, RL, Falk, LJ & Fulco, CS 1987, 'Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m)', Aviation Space and Environmental Medicine, vol. 58, no. 7, pp. 668-672.

Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). / Rock, Paul; Johnson, T. S.; Cymerman, A.; Burse, R. L.; Falk, L. J.; Fulco, C. S.

In: Aviation Space and Environmental Medicine, Vol. 58, No. 7, 01.12.1987, p. 668-672.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m)

AU - Rock, Paul

AU - Johnson, T. S.

AU - Cymerman, A.

AU - Burse, R. L.

AU - Falk, L. J.

AU - Fulco, C. S.

PY - 1987/12/1

Y1 - 1987/12/1

N2 - In a previous controlled study, dexamethasone (DEX) was shown to prevent acute mountain sickness (AMS) during exposure to simulated high altitude. To determine the effect of DEX during actual altitude exposure, 16 young men were treated with either DEX (4 mg every 6 h) or placebo for 48 h prior to and 48 h after being repidly transported from sea level to the summit of Pokes Peak, CO (4,300 m). Symptoms of AMS were evaluated twice daily at Pikes Peak using the Environmental Symptoms Questionnaire and a clinical assessment. During treatment the mean symptom scores were higher for subjects taking placebo in 18 out of 20 comparisons. On an individual basis, 60% of the subjects receiving placebo met the criteria for being 'sick' compared to 31% of subjects receiving DEX. Beginning 24 h after cessation of treatment, DEX subjects experienced a progressive increase in symptom scores which lasted through the end of the altitude sojourn (day 6). The results indicate that DEX is an effective prophylactic treatment for AMS in an actual mountain environment, but that AMS symptoms can occur if the drug is stopped abruptly.

AB - In a previous controlled study, dexamethasone (DEX) was shown to prevent acute mountain sickness (AMS) during exposure to simulated high altitude. To determine the effect of DEX during actual altitude exposure, 16 young men were treated with either DEX (4 mg every 6 h) or placebo for 48 h prior to and 48 h after being repidly transported from sea level to the summit of Pokes Peak, CO (4,300 m). Symptoms of AMS were evaluated twice daily at Pikes Peak using the Environmental Symptoms Questionnaire and a clinical assessment. During treatment the mean symptom scores were higher for subjects taking placebo in 18 out of 20 comparisons. On an individual basis, 60% of the subjects receiving placebo met the criteria for being 'sick' compared to 31% of subjects receiving DEX. Beginning 24 h after cessation of treatment, DEX subjects experienced a progressive increase in symptom scores which lasted through the end of the altitude sojourn (day 6). The results indicate that DEX is an effective prophylactic treatment for AMS in an actual mountain environment, but that AMS symptoms can occur if the drug is stopped abruptly.

UR - http://www.scopus.com/inward/record.url?scp=0023609231&partnerID=8YFLogxK

M3 - Article

C2 - 3619842

AN - SCOPUS:0023609231

VL - 58

SP - 668

EP - 672

JO - Aviation Space and Environmental Medicine

JF - Aviation Space and Environmental Medicine

SN - 0095-6562

IS - 7

ER -